FIELD: biotechnology.
SUBSTANCE: invention relates to the field of immunology, microbiology, and molecular genetics and can be used in the medical industry in the production of vaccines against the SARS-COV-2 virus and diagnostic agents for identification thereof. Substance of the invention consists in creating the recombinant DNA (designated cov1) resulting from polymerase chain reaction (PCR) using synthesised DNA encoding the S-protein of the SARS-CoV-2 coronavirus, unique primers SEQ ID NO: 1 and SEQ ID NO: 2, and the recombinant plasmid pQE-cov1. The recombinant DNA cov1 produced using the expression plasmid pQE-30 in E.coli M15 cells encodes a unique recombinant protein Cov1 with a molecular weight of 24.5±0.5 kDa, wherein said protein causes the formation of antibodies against the protein S of the SARS-CoV-2 coronavirus.
EFFECT: application of the invention results in the creating of a recombinant plasmid DNA pQE-cov1 constituting a plasmid DNA pQE-30, carrier of the recombinant DNA cov1, and an E.coli producer strain M15-Cov1 allowing for production of the recombinant protein Cov1.
4 cl, 7 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ISOLATED RECOMBINANT VIRUS BASED ON INFLUENZA VIRUS FOR INDUCING SPECIFIC IMMUNITY TO INFLUENZA VIRUS AND/OR PREVENTING DISEASES CAUSED BY INFLUENZA VIRUS | 2021 |
|
RU2813150C2 |
| METHOD FOR CREATING LIVE STRAIN OF ENTEROCOCCUS L3-SARS BASED ON BIOLOGICALLY ACTIVE STRAIN OF E. FAECIUM L3 | 2021 |
|
RU2782529C1 |
| RECOMBINANT VACCINE STRAIN FOR LIVE INTRANASAL VACCINE PROVIDING COMBINED PREVENTION OF INFLUENZA AND CORONAVIRUS INFECTIONS | 2022 |
|
RU2782531C1 |
| AAV5-BASED VACCINE FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-COV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-COV-2 | 2020 |
|
RU2760301C1 |
| VACCINE BASED ON AAV5 FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-CoV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2020 |
|
RU2783313C1 |
| MEANS AND METHOD FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY THE SARS-COV-2 VIRUS BASED ON A RECOMBINANT ANTIBODY AND A HUMANIZED MONOCLONAL ANTIBODY | 2021 |
|
RU2769223C1 |
| RECOMBINANT GM PROTEIN CAPABLE OF BINDING Α2-MACROGLOBULIN AND APPLICATION THEREOF AS A LIGAND IN AFFINITY CHROMATOGRAPHY FOR EXTRACTING Α2-MACROGLOBULIN FROM HUMAN BLOOD SERUM | 2019 |
|
RU2758604C2 |
| VACCINE BASED ON AAV5 FOR THE INDUCTION OF SPECIFIC IMMUNITY TO THE SARS-CoV-2 VIRUS AND/OR THE PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2021 |
|
RU2761879C1 |
| VACCINE FOR THE PREVENTION OR TREATMENT OF CORONAVIRUS INFECTION BASED ON A GENETIC CONSTRUCT | 2020 |
|
RU2747762C1 |
| RECOMBINANT DNA OF pG4223 AND PLASMID DNA PQE 30-pG4223, STRAIN OF ESCHERICHIA COLI M 15-G4223 WHICH ENABLE TO OBTAIN G4223 POLYPEPTIDE SELECTIVELY BINDING IgG, AND USE THEREOF IN AFFINE CHROMATOGRAPHY TO ISOLATE IgG | 2017 |
|
RU2715672C2 |
